Cardiovascular disease, together with other diseases of lipid metabolism, remains the number one cause of health problems and mortality. Although much is known about the metabolism and transport of lipoproteins and lipids by cells from the biochemical and cell biology standpoint, the molecular details and mechanisms by which these physiological processes take place remain poorly understood. A detailed structural description of the plasma lipoproteins, their constituent apolipoproteins, and their receptors is crucial to understanding the molecular mechanisms involved in the physiology of lipoprotein metabolism and the pathophysiology of atherosclerosis and other diseases of lipid metabolism. The long-term objectives of this research are to determine this molecular detail and to understand the structure-function relationships underlying these processes. ApoA-I, the major protein of High Density Lipoprotein (HDL), plays important roles in reverse cholesterol transport. Interaction with the ABCA1 transporter removes cholesterol the cell membrane forming the nascent HDL particle. Activation of LCAT by ApoA-I results in cholesterol esterification, and the transformation to the mature HDL particle. Finally, apoA-I is a ligand for the hepatic SR-B1 receptor through which cholesterol is delivered to the liver.
In Specific Aim 1, we will build on or recent advance in understanding of the molecular structure of D(185-243)apoA-I to provide a mechanistic understanding of the molecular features of apoA-1 crucial to understanding the mechanisms of lipid interaction, LCAT binding and activation and HDL formation and function at a molecular level. These studies will use mutations designed through our new structural understanding of apoA-I.
In Specific Aim 2, we will correlate the molecular details derived in Aim 1 with functional studies to understand the molecular mechanisms of HDL formation, LCAT interaction, and cholesterol efflux mediated by ABCA1 and ABCG1. Thus, the molecular hypotheses formulated and studied from the structural standpoint in Specific Aim 1, will be probed at the functional level in Specific Aim 2. Our structural studies will provide critical knowledge on these processes. The outcome on completion of these aims will be a significant enhancement in our understanding of the molecular details and interactions of the crucial players in reverse cholesterol transport and metabolism that will drive our ability to develop molecularly based strategies to prevent or control dyslipoproteinemias and diseases of lipid metabolism.

Public Health Relevance

Understanding in molecular detail the processes of lipid transport, cellular uptake and metabolic regulation is crucial to understanding how these processes occur in the healthy state and become dysregulated in diseases of lipid metabolism, such as atherosclerosis. This fundamental knowledge of the key biological processes is expected to facilitate new molecular approaches to the treatment of these major human diseases.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL116518-02
Application #
8901282
Study Section
Vascular Cell and Molecular Biology Study Section (VCMB)
Program Officer
Liu, Lijuan
Project Start
2014-08-01
Project End
2018-06-30
Budget Start
2015-07-01
Budget End
2016-06-30
Support Year
2
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Boston University
Department
Physiology
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
Melchior, John T; Walker, Ryan G; Cooke, Allison L et al. (2017) A consensus model of human apolipoprotein A-I in its monomeric and lipid-free state. Nat Struct Mol Biol 24:1093-1099
Gorshkova, Irina N; Atkinson, David (2017) Increased Binding of Apolipoproteins A-I and E4 to Triglyceride-Rich Lipoproteins is linked to Induction of Hypertriglyceridemia. JSM Atheroscler 2:
Das, Madhurima; Wilson, Christopher J; Mei, Xiaohu et al. (2017) Structural stability and local dynamics in disease-causing mutants of human apolipoprotein a-I: what makes the protein amyloidogenic? Amyloid 24:11-12
Das, Madhurima; Wilson, Christopher J; Mei, Xiaohu et al. (2016) Structural Stability and Local Dynamics in Disease-Causing Mutants of Human Apolipoprotein A-I: What Makes the Protein Amyloidogenic? J Mol Biol 428:449-62
Mei, Xiaohu; Liu, Minjing; Herscovitz, Haya et al. (2016) Probing the C-terminal domain of lipid-free apoA-I demonstrates the vital role of the H10B sequence repeat in HDL formation. J Lipid Res 57:1507-17
Mei, Xiaohu; Atkinson, David (2015) Lipid-free Apolipoprotein A-I Structure: Insights into HDL Formation and Atherosclerosis Development. Arch Med Res 46:351-60
Wang, Libo; Mei, Xiaohu; Atkinson, David et al. (2014) Surface behavior of apolipoprotein A-I and its deletion mutants at model lipoprotein interfaces. J Lipid Res 55:478-92
Gorshkova, Irina N; Mei, Xiaohu; Atkinson, David (2014) Binding of human apoA-I[K107del] variant to TG-rich particles: implications for mechanisms underlying hypertriglyceridemia. J Lipid Res 55:1876-85
Das, Madhurima; Mei, Xiaohu; Jayaraman, Shobini et al. (2014) Amyloidogenic mutations in human apolipoprotein A-I are not necessarily destabilizing - a common mechanism of apolipoprotein A-I misfolding in familial amyloidosis and atherosclerosis. FEBS J 281:2525-42
Gursky, Olga; Jones, Martin K; Mei, Xiaohu et al. (2013) Structural basis for distinct functions of the naturally occurring Cys mutants of human apolipoprotein A-I. J Lipid Res 54:3244-57